{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:26:36Z","timestamp":1759335996718,"version":"3.32.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1097\/01.aids.0000192086.64432.e7","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T08:01:56Z","timestamp":1130313716000},"page":"S166-S173","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of hepatitis C virus in HIV patients: a review"],"prefix":"10.1097","volume":"19","author":[{"given":"Nickolas","family":"Kontorinis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushik","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas T","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-25-20210130","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R2-25-20210130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R3-25-20210130","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-25-20210130","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1089\/088922203771881176","article-title":"Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin","volume":"19","author":"Perez-Olmeda","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R5-25-20210130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0163-4453(94)94440-7","article-title":"High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain","volume":"28","author":"Soriano","year":"1994","journal-title":"J Infect"},{"key":"R6-25-20210130","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"R7-25-20210130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"R8-25-20210130","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1086\/323009","article-title":"Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus","volume":"33","author":"Soriano","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R9-25-20210130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00042560-200007010-00003","article-title":"Mortality for liver disease in patients with HIV infection: a cohort study","volume":"24","author":"Puoti","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-25-20210130","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","article-title":"Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C","volume":"34","author":"Poynard","year":"2001","journal-title":"J Hepatol"},{"key":"R11-25-20210130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-2003-39948","article-title":"Toxicity of non-nucleoside analogue reverse transcriptase inhibitors","volume":"23","author":"Kontorinis","year":"2003","journal-title":"Semin Liver Dis"},{"key":"R12-25-20210130","first-page":"36","article-title":"Hepatotoxicity of antiretroviral therapy","volume":"5","author":"Kontorinis","year":"2003","journal-title":"AIDS Rev"},{"key":"R13-25-20210130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"R14-25-20210130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2893.2001.00280.x","article-title":"Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature","volume":"8","author":"Colin","year":"2001","journal-title":"J Viral Hepat"},{"issue":"Suppl. 8","key":"R15-25-20210130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ndt\/15.suppl_8.15","article-title":"Diagnostic tests for hepatitis C virus infection","volume":"15","author":"Barrera","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R16-25-20210130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000462880","article-title":"Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA","volume":"68","author":"Barrera","year":"1995","journal-title":"Vox Sang"},{"issue":"Suppl. 2","key":"R17-25-20210130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-2004-832923","article-title":"Use of diagnostic testing for managing hepatitis C virus infection","volume":"24","author":"Ferreira-Gonzalez","year":"2004","journal-title":"Semin Liver Dis"},{"key":"R18-25-20210130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00126334-200210010-00005","article-title":"Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.","volume":"31","author":"George","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-25-20210130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/JCM.38.2.575-577.2000","article-title":"Screening for hepatitis C virus in human immunodeficiency virus-infected individuals.","volume":"38","author":"Thio","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"Suppl. 1","key":"R20-25-20210130","first-page":"47","article-title":"Implications of peginterferon use in special populations infected with HCV","volume":"23","author":"Sherman","year":"2003","journal-title":"Semin Liver Dis"},{"key":"R21-25-20210130","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"R22-25-20210130","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R23-25-20210130","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/341976","article-title":"Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus","volume":"35","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R24-25-20210130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2893.1999.00153.x","article-title":"Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA","volume":"6","author":"Bonacini","year":"1999","journal-title":"J Viral Hepat"},{"key":"R25-25-20210130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/hep.510300131","article-title":"Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease","volume":"30","author":"Sherman","year":"1999","journal-title":"Hepatology"},{"key":"R26-25-20210130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-2893.2000.00196.x","article-title":"Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study","volume":"7","author":"Hino","year":"2000","journal-title":"J Viral Hepat"},{"key":"R27-25-20210130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/clinids\/23.3.585","article-title":"Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group","volume":"23","author":"Soriano","year":"1996","journal-title":"Clin Infect Dis"},{"key":"R28-25-20210130","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jhep.2003.11.004","article-title":"The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients","volume":"40","author":"Patton","year":"2004","journal-title":"J Hepatol"},{"key":"R29-25-20210130","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"R30-25-20210130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/apc.1999.13.395","article-title":"Altered body shape in HIV disease: a side effect of therapy?","volume":"13","author":"Baker","year":"1999","journal-title":"AIDS Patient Care STDS"},{"issue":"Suppl. 2","key":"R31-25-20210130","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1086\/313854","article-title":"HIV protease inhibitor-related lipodystrophy syndrome","volume":"30","author":"Carr","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R33-25-20210130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.510300319","article-title":"Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group","volume":"30","author":"Reddy","year":"1999","journal-title":"Hepatology"},{"key":"R34-25-20210130","first-page":"1374","article-title":"Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers","volume":"91","author":"Ohnishi","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R35-25-20210130","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R36-25-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl. 11","key":"R37-25-20210130","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1053\/jlts.2003.50257","article-title":"The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host","volume":"9","author":"Braun","year":"2003","journal-title":"Liver Transplant"},{"key":"R38-25-20210130","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1001\/archinte.160.22.3365","article-title":"Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues","volume":"160","author":"Bonacini","year":"2000","journal-title":"Arch Intern Med"},{"key":"R40-25-20210130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/00126334-200404150-00004","article-title":"Daily versus thrice-weekly interferon Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial","volume":"35","author":"Sulkowski","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R41-25-20210130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/hep.20107","article-title":"Treatment of chronic hepatitis C in HIV\/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin","volume":"39","author":"Brau","year":"2004","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"R42-25-20210130","first-page":"23","article-title":"Pharmacokinetics of peginterferons","volume":"23","author":"Zeuzem","year":"2003","journal-title":"Semin Liver Dis"},{"key":"R43-25-20210130","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"Perez-Olmeda","year":"2003","journal-title":"AIDS"},{"issue":"Suppl. 1","key":"R46-25-20210130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/jhep.2002.36810","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"R47-25-20210130","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1086\/340199","article-title":"Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients","volume":"185","author":"Dieterich","year":"2002","journal-title":"J Infect Dis"},{"key":"R48-25-20210130","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(00)04920-5","article-title":"Mitochondrial toxic effects and ribavirin","volume":"357","author":"Kakuda","year":"2001","journal-title":"Lancet"},{"key":"R49-25-20210130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00002030-200204120-00001","article-title":"Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV\u2013HCV International Panel","volume":"16","author":"Soriano","year":"2002","journal-title":"AIDS"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00001665-200601000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:03:13Z","timestamp":1736056993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200510003-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":45,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.aids.0000192086.64432.e7","relation":{},"ISSN":["0269-9370"],"issn-type":[{"type":"print","value":"0269-9370"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}